On Nov 07, major Wall Street analysts update their ratings for $CRISPR Therapeutics (CRSP.US)$, with price targets ranging from $30 to $95.
Evercore analyst Liisa Bayko maintains with a hold rating, and maintains the target price at $60.
TD Cowen analyst Tyler Van Buren maintains with a sell rating, and maintains the target price at $30.
Oppenheimer analyst Jay Olson maintains with a buy rating, and maintains the target price at $95.
Stifel analyst Benjamin Burnett maintains with a hold rating, and adjusts the target price from $59 to $53.
Truist Financial analyst Joon Lee maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $CRISPR Therapeutics (CRSP.US)$'s main analysts recently are as follows:
Crispr Therapeutics' third-quarter update underscored the CTX112 ASH abstract in B-cell malignancies, showcasing promising initial efficacy.
The journey for patients using Casgevy isn't brief, yet there are indications of demand starting to emerge. Notably, beyond the first patient infusion, 40 patients have completed at least one cell collection. Analysts remain cautious as they continue to evaluate the time needed to translate patient treatments into revenue and profitability. Looking ahead, the CTX112 ASH2024 abstract showed a 6-month complete response rate of 44% in a mixed lymphoma study. Further insight is anticipated upon full disclosure to better assess the drug's potential in the fields of oncology and autoimmune diseases.
Here are the latest investment ratings and price targets for $CRISPR Therapeutics (CRSP.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月7日，多家華爾街大行更新了$CRISPR Therapeutics (CRSP.US)$的評級，目標價介於30美元至95美元。
Evercore分析師Liisa Bayko維持持有評級，維持目標價60美元。
TD Cowen分析師Tyler Van Buren維持賣出評級，維持目標價30美元。
奧本海默控股分析師Jay Olson維持買入評級，維持目標價95美元。
斯迪富分析師Benjamin Burnett維持持有評級，並將目標價從59美元下調至53美元。
儲億銀行分析師Joon Lee維持買入評級。
此外，綜合報道，$CRISPR Therapeutics (CRSP.US)$近期主要分析師觀點如下：
Crispr therapeutics的第三季度更新突出了在b細胞惡性腫瘤中的CTX112 ASH摘要，展示了具有很好初步功效。
使用Casgevy的患者之路並不簡短，然而，有跡象表明需求開始出現。值得注意的是，除了第一個病人輸入外，還有40名患者完成了至少一次電芯收集。分析師仍然謹慎，因爲他們持續評估將患者治療轉化爲營業收入和盈利所需的時間。展望未來，CTX112 ASH2024摘要顯示，在混合淋巴瘤研究中的6個月完全緩解率達到了44%。更全面的信息披露後，預計能夠更好地評估這種藥物在腫瘤學和自身免疫疾病領域的潛力。
以下爲今日5位分析師對$CRISPR Therapeutics (CRSP.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
